Author

Minal A. Patel

Memorial Sloan Kettering Cancer Center

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Genetic & Genomic Medicine· 1 Genetics· 1 Genomics· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 3 Approach:statistical model· 3 Research Focus:variant calling· 2 Assay:whole-genome sequencing· 2 Approach:benchmark study· 1 Research Focus:differential expression· 1 Assay:DNA methylation· 1 Research Focus:GWAS / association mapping· 1

Frequent Co-Authors

Elli PapaemmanuiliD· 3 shared Gunes GundemiD· 3 shared Juan Santiago Medina-MartineziD· 3 shared Max Fine LevineiD· 3 shared Benjamin L. EbertiD· 2 shared Elsa BernardiD· 2 shared Juan E. Arango· 2 shared Kelly L. BoltoniD· 2 shared

Activity by Year

2019-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersGenetic & Genomic Medicine

Elli PapaemmanuilORCID

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Whole Genome Landscape Analysis of Homologous Recombination Deficiency in a Pan-Cancer Cohort

Majd Al Assaad, Kevin Hadi, Max Fine Levine, Daniela E. Guevara, Minal A. Patel, Marvel Tranquille, Abigail S. King, John R. Otilano, Alissa Semaan, Gunes Gundem, Juan Santiago Medina-Martinez, Michael Sigouros, Jyothi Manohar, Hui–Hsuan Kuo, David C. Wilkes, , Juan Miguel Mosquera

The paper analyzes whole-genome sequencing data from a pan-cancer cohort to define HRD, showing it extends beyond BRCA1/2 mutations and highlights the benefits of WGS over commercial assays for HRD detection.

medRxiv · Jun 28, 2024 · PreprintGenetic & Genomic Medicine

Implications of TP53 Allelic State for Genome Stability, Clinical Presentation and Outcomes in Myelodysplastic Syndromes

Elsa Bernard, Yasuhito Nannya, Robert Paul Hasserjian, Sean M. Devlin, Heinz Tuechler, Juan Santiago Medina-Martinez, Tetsuichi Yoshizato, Yusuke Shiozawa, Ryunosuke Saiki, Luca Malcovati, Max Fine Levine, Juan E. Arango, Yangyu Zhou, Francesc Gessé Solé, Catherine A. Cargo, , Elli Papaemmanuil

The paper examines TP53 allelic states in MDS patients, finding that bi-allelic targeting is linked to worse outcomes, while mono-allelic targeting does not differ from wild-type patients.

Nature Medicine · Aug 3, 2020Peer-reviewedGenomics

Oncologic Therapy Shapes the Fitness Landscape of ClonalHematopoiesis

Kelly L. Bolton, Ryan N. Ptashkin, Teng Gao, Lior Zvi Braunstein, Sean M. Devlin, Daniel John Kelly, Minal A. Patel, Antonin Berthon, Aijazuddin Syed, Mariko Yabe, Catherine Callaghan Coombs, Nicole M. Caltabellotta, Mike Walsh, Kenneth Offit, Zsofia Kinga Stadler, , Elli Papaemmanuil

The paper shows oncologic therapy increases clonal hematopoiesis with DDR mutations, which predicts risk of therapy-related myeloid neoplasms.

bioRxiv · Nov 20, 2019 · PreprintGenetics